Trial Profile
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Capecitabine; Cetuximab; Panitumumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma Oncology
- 16 Jun 2021 Time frame for primary endpoint changed from 8 weeks to 24 months.
- 20 Jan 2020 Status changed from active, no longer recruiting to completed.
- 30 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Nov 2019.